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A novel and rapid flow injection chemiluminescence (FI-CL) method was established for the
determination of doxorubicin, whichwas based on the phenomenon that CL intensity of the
reaction between K3Fe(CN)6 and luminol in alkaline solution could be strongly enhanced by
doxorubicin. Under optimum conditions, the relative CL intensity of the system was linear
with the concentration of doxorubicin in the range from 2.0  109 g/mL to 5.0  107 g/mL
with a correlation coefficient of 0.9993 (n¼ 9). The detection limit (3s) was 4.25 1010 g/mL,
and the relative standard deviation (RSD) for 1.0 107 g/mL doxorubicin (n¼ 11) was 0.33%.
Themethodwas applied to the determination of doxorubicin in pharmaceutical preparation
and rat plasma, and the percentage recovery of doxorubicin in rat plasmawasbetween89.8%
and 102.2%. The possible CL mechanism was also discussed briefly.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.Open access under CC BY-NC-ND license.1. Introduction Several analytical methods have been reported for theDoxorubicin is a cytotoxic anthracycline antibiotic widely
used in acute lymphocytic leukemia and various carcinomas
[1]. However, the clinical use of doxorubicin is limited by a
cumulative dose-dependent irreversible chronic cardiomy-
opathy, which can subsequently lead to congestive heart
failure, with an ultimate mortality rate of 20e40% [2,3].
Therefore, for its potential pharmaceutical effects on
health, the development of a simple, rapid, and sensitive
method for the determination of doxorubicin in pharma-
ceutical preparations and biological fluids would be highly
desirable.ceutical Sciences, Zhengz
ao).
ministration, Taiwan. Publdetermination of doxorubicin in real samples, including high-
performance liquid chromatography (HPLC) [4e7], ultraviolet-
visible (UV-vis) spectrophotometry [8,9], and fluorescence
detection [10e12]. However, these methods suffered from the
disadvantages of low sensitivity and narrow linear range, or
were time consuming. In recent years, the sensitive analyt-
ical technique based on chemiluminescence (CL) systems has
received considerable attention with the characteristics of
low detection limit, wide calibration range, and short anal-
ysis time. Although the CL method has been successfully
applied to the analysis of pharmaceutical compounds and
biological samples, the reports concerning the use of the CLhou University, Zhengzhou 450001, PR China.
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Fig. 1 e Schematic diagram of the flow injection
chemiluminescence system for the determination of
doxorubicin. a [ K3Fe(CN)6; b [ water; c [ luminol;
d[ doxorubicin; D[ detector; F[ flow cell; P[ peristaltic
pump; PC [ personal computer; V [ valve; W [ waste.
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Ahmed et al. [15] reported a selective HPLC method for the
determination of doxorubicin and its metabolite doxor-
ubicinol in rat plasma. The method was based on photo-
sensitization reaction followed by peroxyoxalate CL
detection. A comparison of analytical figures of merit of the
proposed method with previously reported methods is
shown in Table 1[4,8,9,15].
In the current study, a new and sensitive CLmethod for the
rapid determination of doxorubicin was developed, which
was based on the enhanced effect exerted by doxorubicin on
the luminol-K3Fe(CN)6 CL reaction. The proposed approach
offered good accuracy and precision, which was successfully
used for the determination of doxorubicin in the commercial
preparation and biological fluid. The possible mechanismwas
also discussed briefly.2. Methods
2.1. Apparatus and reagents
CL measurements were carried out by means of a flow injec-
tion CL analyzer, including a model IFFM-E flow injection
system and a model IFFS-A luminometer (Xi’an, Ruimai Elec-
tronic Company, Xi’an, China). The CL spectra were acquired
on a model RF-5301 spectrofluorometer (SHIMADZU Enter-
prise Management Co., Ltd., Shimadzu, Japan). UV-vis ab-
sorption spectra were acquired on a UV-2550 spectrometer
(SHIMADZU Enterprise Management Co., Ltd., Shimadzu,
Japan).
All the reagents were of analytical grade and all solutions
wereprepared inMilli-Q (TheMilliporeultrapurewaterCo.,Ltd.,
Millipore, U.S.A) ultrapure water. Doxorubicin was purchased
from Dalian Meilun Biology Technology Company (Dalian,
China). A 1.0  104 g/mL doxorubicin stock solution was pre-
pared by dissolving 0.01000 g doxorubicin in water and
diluting to 100 mL, and the working solution was diluted from
the stock solution as required. A 1.0  102 M luminol solution
was prepared by dissolving 0.17716 g luminol (Beijing Solarbio
Science & Technology Co., Ltd., Beijing, China) in 100 mL 1.0M
NaOH. The working solution of luminol was prepared by
diluting luminol with the appropriate NaOH solution contain-
ing K4Fe(CN)6 solution. Stock solutions of 5.0 103MK3Fe(CN)6
and 0.2MK4Fe(CN)6 were also prepared and diluted with water.Table 1 e The reported methods and the proposed method for
Methods Linear range (g/mL) Limit o
detection (g
HPLC 1.0  108e2.0  106 6.25  10
Visible
spectrophotometry
4.0  107e4.0  106 3.4  10
CE 1.16  108e2.9  107 5.8  10
HPLC-PO-CL 1.16  109e5.8  107 2.61  10
FI-CL 2.0  109e5.0  107 4.25  10
CE ¼ capillary electrophoresis; FI-CL ¼ flow injection chemilumin
CL ¼ peroxyoxalate chemiluminescence.2.2. Procedures
As shown in Fig. 1, one peristaltic pump was used to carry
K3Fe(CN)6 solution, and another to carry luminol solution,
sample solution, and carrier stream. The pumps started to
wash the whole flow system until a stable baseline was ach-
ieved. The flow rate was set at 1.5 mL/min for all lines.
Luminol solution [with K4Fe(CN)6 in NaOH solution] and
sample solution were pumped into the mixing element. The
K3Fe(CN)6 solution was simultaneously injected into the car-
rier stream (water) through a six-way injection valve, and then
merged into themixed stream of luminol solution and sample
solution. Finally, the mixtures reacted in the flow cell to
generate the CL signal. The concentration of doxorubicin was
quantified based upon the net CL intensity changes (DICL),
DICL ¼ Is  I0, where Is and I0 are the CL intensities of the
doxorubicin and blank solution, respectively.2.3. Plasma sample preparation
Whole blood was collected from healthy Sprague-Dawley rats
weighing 200e250 g (Experimental Animal Center of Henan
Province) after injection via a tail vein. After the centrifugation
at 3,500 rpm for 5 minutes, the supernatant was collected as
plasma samples. In addition, 0.1 mL ethanol and 0.3 mLthe determination of doxorubicin.
f
/mL)
Sample matrix References
9 Human plasma sample [4]
8 Pharmaceutical preparations [8]
10 Human plasma sample [9]
15 Rat plasma sample [15]
10 Pharmaceutical preparations
and rat plasma sample
Proposed method
escence; HPLC ¼ high-performance liquid chromatography; PO-
Fig. 2 e Chemiluminescence (CL) kinetic curves. (A) CL
emission of luminol and K3Fe(CN)6. (B) CL emission of
doxorubicin and mixture of luminol and K3Fe(CN)6.
Conditions: luminol, 5.0 3 10L5M; K3Fe(CN)6, 3.0 3 10
L5M;
doxorubicin, 1.0 3 10L6 g/mL.
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vortexed for 1 minute. The mixture was centrifuged at
10,000 rpm for 10 minutes and the organic layer was trans-
ferred into the tube. The organic layer was left to evaporate to
dryness under nitrogen. The residue was dissolved in water
and diluted appropriately within the linear range of the
determination.3. Results and discussion
3.1. Kinetic characteristics of the reaction
The kinetic behavior of the CL reaction of luminol-K3Fe(CN)6
-doxorubicin was studied by a static method. As shown in
Fig. 2, when 3.0  105M K3Fe(CN)6 solution was injected into
luminol solution, a CL reaction was initiated immediately.
Subsequently, a stronger CL signal was observed whenTable 2 e Results and design of the orthogonal experiment.
No. Factor
Concentration of
NaOH (M)
Concentration of
luminol (105M)
Concentrati
K4Fe(CN)6
1 0.1 4.0 0.004
2 0.1 5.0 0.005
3 0.1 6.0 0.006
4 0.2 4.0 0.005
5 0.2 5.0 0.006
6 0.2 6.0 0.004
7 0.3 4.0 0.006
8 0.3 5.0 0.004
9 0.3 6.0 0.005
K1 3076 6369 11648.5
K2 8253.5 9382 5655.5
K3 10481 6059.5 4506.5
R 2468.3 1107.5 2380.7
Ki is the sum of the evaluation indexes of all levels (i ¼ 1, 2, 3) in each fa
R is the range between the maximum and minimum value of Ki.K3Fe(CN)6 solution was injected into the mixed solution of
luminol and doxorubicin. These findings indicated that the
doxorubicin enhanced the CL intensity dramatically, and the
rate of the reaction was so fast that the CL intensity reached
the maximum value within 2.5 seconds.
3.2. Optimization of CL reactions
3.2.1. Single factor experiment
In order to optimize conditions for the determination of
doxorubicin, variousparameters, including theconcentrations
of luminol, NaOH, K3Fe(CN)6, and K4Fe(CN)6, were investigated
first using a univariate approach. The studied range was
selected based on the influence of variable on the CL signal,
and the optimizing criterion was based on the maximum
signal and good repeatability. All of these experiments were
performed with a 1.0  107 g/mL doxorubicin standard solu-
tion and a photomultiplier tube (PMT) voltage of 800 V.
The experimental results showed that the relative CL in-
tensity reached the maximum value when the K3Fe(CN)6
concentration was 2.0  105 M. However, the CL signal
increased rapidly with the increasing the concentration of
NaOH and luminol under the selected range. Moreover,
K4Fe(CN)6 can effectively decrease the blank signal and in-
crease the stability of the CL reaction. Therefore, it is not
possible to obtain the optimal concentrations of luminol,
NaOH and K4Fe(CN)6 by the single factor test, and with the
consideration of reproducibility and linearity, an orthogonal
experiment was thus designed to obtain the optimum
conditions.
3.2.2. Orthogonal experiment
According to the results of the single factor test, an orthogonal
experiment (four factors and three levels) was designed and
the studied factors were the concentrations of NaOH, luminol,
K3Fe(CN)6, and K4Fe(CN)6. The influences of variables were
studied by the range analysis. As shown in Table 2, K3Fe(CN)6
was the most important factor, following by NaOH, luminol,Is I0 DICL
on of
(M)
Concentration of
K3Fe(CN)6 (105M)
1.0 124.5 0 124.5
2.0 834 0 834
3.0 2631.5 514 2117.5
3.0 5261.5 932 4329.5
1.0 579 105 474
2.0 4312.5 862.5 3450
2.0 2620.5 705.5 1915
3.0 9918 1844 8074
1.0 852 360 492
1090.5
6199
14521
4476.8
ctor;
Fig. 3 e (A) The effect of NaOH. (B) Luminol concentration. (C) K3Fe(CN)6 concentration. (D) K4Fe(CN)6 concentration on
chemiluminescence (CL) intensity. Conditions: doxorubicin, 1.0 3 10L7 g/mL.
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NaOH, 5.0  105M of luminal, and 0.004M K4Fe(CN)6 were the
optimal combination of this study. Moreover, another single
factor experiment was performed to verify the optimal con-
ditions, which were obtained by the above orthogonal exper-
iment. As shown in Fig. 3, the optimized conditions coincided
with the results of the orthogonal experiment, and the
reproducibility and linear relationship of the systemwere also
satisfactory.
3.3. Analytical characteristics
Under the above optimum conditions, calibration graph over
the range of 2.0  109 g/mL to 5.0  107 g/mL doxorubicin
with a correlation coefficient of 0.9993 was obtained. The
regression equation was I ¼ 580.24 þ 688.25  108 C, (C, g/mL).
The detection limit, as defined by the International UnionTable 3 e Results of determination of doxorubicin in injection
Sample Added
(107 g/mL)
Founda
(107 g/mL)
1 0.00 1.08
0.80 1.91
1.00 2.12
1.20 2.23
2 0.00 1.08
0.80 1.89
1.00 2.04
1.20 2.27
a Average of five measurements [ relative standard deviation (RSD)].of Pure and Applied Chemistry (IUPAC), was determined to be
4.25  1010 g/mL, and the relative standard deviation
(RSD) was 0.33%, which was obtained from a series of 11
standards each containing 1.0 107 g/mL of doxorubicin. The
sample measurement frequency was calculated about 120
samples h1.
3.4. Interference
The influences of different metal ions and some excipients
used in pharmaceutical preparations on the CL intensity were
investigated by determining the CL emission of the solutions
containing 1.0  107 g/mL doxorubicin and foreign species.
The tolerance limit of the foreign species was taken as a
relative error 5% in the peak height. The results indicated
that 1,000-fold CaCl2, KCl, (NH4)2SO4, lactose and glucose, 500-
fold sodium citrate and sodium carbonate, 200-fold Mg2þ ands.
RSD
(%)
Recovery
(%)
Content
(mg/injection)
0.3 10.8
1.4 103.8
0.3 104.0
0.2 95.8
0.7 10.8
0.6 101.3
0.8 96.0
0.5 99.2
Table 4 e Determination of doxorubicin in spiked plasma
samples.
Sample Added
(107 g/mL)
Founda
(107 g/mL)
Recovery
(%)
RSD
(%)
1 0.50 0.48 96.0 0.4
2 1.00 1.00 100.0 0.2
3 2.00 2.05 102.5 1.2
a Average of five measurements [ relative standard deviation
(RSD)].
Fig. 4 e The chemiluminescence emission spectra. (A)
Luminol-K3Fe(CN)6. (B) Luminol-K3Fe(CN)6-doxorubicin.
Conditions: luminol, 5.0 3 10L5M; K3Fe(CN)6, 3.0 3 10
L5M;
doxorubicin, 1.0 3 10L6 g/mL.
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determination of doxorubicin in this system. The interference
of protein in plasma could be eliminated by protein precipi-
tation as described for the plasma sample preparation.
Therefore, the current method could be applied to the deter-
mination of doxorubicin in pharmaceutical preparations and
rat plasma.
3.5. Sample analysis
3.5.1. Determination of doxorubicin in injections
The proposed method for the determination of doxorubicin
was applied to the commercial pharmaceutical formulation.
Two different batch numbers of doxorubicin injections (Zhe-
jiang Hisun Pharmaceutical Co. Ltd, Taizhou, China) were
diluted appropriately with water prior to measurement, so
that the concentration of doxorubicin was in its linear
response range. To validate the developed method, the re-
covery of doxorubicin was examined by spiking known
amounts of doxorubicin into the sample solutions. The results
were listed in Table 3 with an acceptable recovery range of
95.8e104.0%.
3.5.2. Determination of doxorubicin in rat plasma
First, the extraction recovery was examined on plasma sam-
ples spiked with known amounts of standard doxorubicin.
The results were listed in Table 4, with recoveries of
96.0e102.5%, indicating a suitable extraction method for
doxorubicin in plasma.
The proposedmethodwas then used for the determination
of doxorubicin in rat plasma after injection at a dose of 5 mg/
kg via a tail vein. Blood sampleswere obtained from the orbital
vein right after injection of the drug. According to the proce-
dure for the plasma samples treatment, the final samples
were obtained and analyzed by the proposedmethod with the
standard addition. The recoveries were obtained ranging from
89.8% to 102.2%, as shown in Table 5. It can be seen that the
developed method can be easily performed and affords good
precision and accuracy when applied to the plasma samples.Table 5 e Determination of doxorubicin in plasma samples (n
Sample Content
(106 g/mL)
Added
(106 g/mL)
1 3.50 5.00
2 3.22 5.00
3 3.78 5.003.6. Possible reaction mechanism
The CL reaction system of luminol and K3Fe(CN)6 has been
extensively studied. It was confirmed that the excited state
of 3-aminophthalate, which was the oxidation product of
luminol, was the emitter in this system and the maximum
wavelength of CL emission spectra of the system was
425 nm [16]. In order to explore the possible mechanism of
luminol-K3Fe(CN)6-doxorubicin system, the following ex-
periments were performed. First, the CL emission spectra
were examined on an RF-5301 model spectrofluorometer
whose excitation lamp was shut off. As shown in Fig. 4, the
maximum emission wavelength of the luminol-K3Fe(CN)6 or
luminol-K3Fe(CN)6-doxorubicin was located at 425 nm, and
doxorubicin just increased the relative CL intensity. There-
fore, we deduced that doxorubicin did not change the
mechanism of the CL reaction, the luminophor was still the
excited state of 3-aminophthalate, and the addition of
doxorubicin did not lead to the generation of a new lumi-
nophor for this system. Next, UV-vis absorption spectra of
luminol, K3Fe(CN)6, and doxorubicin were measured, as
depicted in Fig. 5. It can be seen that doxorubicin had two
notable absorption peaks at about 233 nm and 253 nm
(Fig. 5C), and luminol had two distinct absorption peaks at
296 nm and 346 nm (Fig. 5B). The addition of doxorubicin to
luminol revealed that no complex formed between the
species and the absorption spectrum of the mixture system
was approximately the sum of these two individual spectra
(Fig. 5A). However, the absorption of K3Fe(CN)6 decreased
after doxorubicin was added into it, which implied that the[ 3).
Found
(106 g/mL)
Recovery
(%)
Relative standard
deviation (%)
7.99 89.8 2.3
8.33 102.2 0.5
8.57 95.8 0.4
Fig. 5 e Ultraviolet-visible spectra. (A) Luminol-
doxorubicin. (B) Luminol. (C) Doxorubicin. (D) K3Fe(CN)6. (E)
K3Fe(CN)6-doxorubicin. Conditions: luminol, 5.0 3 10
L5M;
K3Fe(CN)6, 3.0 3 10
L5M; doxorubicin, 1.0 3 10L6 g/mL.
Luminol2- Fe(CN)63-+
Doxorubicin + Fe(CN)63- Doxorubicin* + Fe(CN)64-
Luminol* + Fe(CN)64-
Doxorubicin* + Luminol2-
O2 Luminol* + Doxorubicin
Luminol * Luminol2- + hv (425nm)
Scheme 1 e The possible mechanism for the luminol-
K3Fe(CN)6- doxorubicin system.
j o u rn a l o f f o o d a nd d r u g an a l y s i s 2 1 ( 2 0 1 3 ) 2 7 9e2 8 5284reaction occurred between doxorubicin and K3Fe(CN)6
(Fig. 5E).
Several papers have reported that polyphenol can be
oxidized to phenoxy radicals and produce energy that induces
the transition of phenoxy radicals from its ground state to an
excited electronic state [17e20]. Doxorubicin, an anthracy-
cline glycoside antibiotic that contains phenolic hydroxyl, can
be easily oxidized to its excited state by strong oxidant.
Therefore, according to the aforementioned experiments and
discussion, the possible enhancement mechanism of doxo-
rubicin in the systemmay be concluded as follows (Scheme 1):
doxorubicin can be oxidized and produce energy that induces
the transition of oxidized doxorubicin from its ground state to
an excited electronic state. When the excited oxidized doxo-
rubicin molecule returns to the ground state, it could transfer
energy to the ground state of 3-aminophthalate ions, and form
more excited 3-aminophthalate ions, which return to the
ground state with enhanced CL phenomena.4. Conclusion
A rapid and simple flow injection chemiluminescence tech-
nique for the determination of doxorubicin with luminol andK3Fe(CN)6 systemwas established for the first time. Compared
with other methods, the current work had a high sensitivity,
good precision, convenience, and wide linear range. It
has been successfully applied to the determination of doxo-
rubicin in pharmaceutical preparation and rat plasma, and
was potentially useful for analysis of doxorubicin in more
complicated biological samples.r e f e r e n c e s
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